Eupraxia Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:EPRXF) C$4.23 0.00 (0.00%) (As of 12/5/2023 ET) Add Compare Share Share Today's RangeC$4.23▼C$4.2350-Day RangeC$3.96▼C$5.5252-Week RangeC$2.69▼C$6.78VolumeN/AAverage Volume2,316 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetC$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest About Eupraxia Pharmaceuticals Stock (OTCMKTS:EPRXF)Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.Read More EPRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPRXF Stock News HeadlinesNovember 9, 2023 | markets.businessinsider.comVerrica Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 1, 2023 | markets.businessinsider.comMirum Pharmaceuticals earnings preview: what Wall Street is expectingDecember 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 1, 2023 | finance.yahoo.comEupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyOctober 27, 2023 | marketwatch.comDechra Pharmaceuticals rises Friday, outperforms marketOctober 26, 2023 | marketwatch.comWest Pharma Cuts 2023 Sales View, Boosts Adjusted Earnings View, as Ordering Trends ChangeOctober 12, 2023 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc WT down on Wednesday (EPRX-WT)October 11, 2023 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc WT down on Tuesday (EPRX-WT)December 6, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 11, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisOctober 2, 2023 | seekingalpha.comSyndax Pharma falls after early data for leukemia therapySeptember 29, 2023 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc down on Friday (EPRX)September 25, 2023 | cnbc.comJefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunitiesSeptember 20, 2023 | marketwatch.comDechra Pharmaceuticals rises Wednesday, still underperforms marketSeptember 20, 2023 | msn.comDirexion Daily Pharmaceutical & Medical Bull 3X Shares declares quarterly distribution of $0.0353September 7, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Announces Change of AuditorSeptember 7, 2023 | marketwatch.comDechra Pharmaceuticals remains steady Thursday, underperforms marketSeptember 6, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023August 11, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Myriad Genetics (MYGN)August 4, 2023 | marketwatch.comEupraxia Pharmaceuticals Shares Climb With Plans for Private PlacementAugust 4, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 MillionJuly 25, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Syndax Pharmaceuticals (SNDX) and Kodiak Sciences (KOD)July 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Ascendis Pharma (ASND)June 26, 2023 | finance.yahoo.comEupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IARJune 13, 2023 | marketwatch.comEupraxia Shares Climb After FDA Fast-Track Designation for StudyJune 13, 2023 | marketwatch.comEupraxia Pharmaceuticals Gets FDA Fast-Track Designation for EP-104IAR StudySee More Headlines Receive EPRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:EPRXF CUSIPN/A CIKN/A Webwww.eupraxiapharma.com Phone250 590 3968FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price TargetC$18.00 High Stock Price TargetC$18.00 Low Stock Price TargetC$18.00 Potential Upside/Downside+326.0%Consensus RatingStrong Buy Rating Score (0-4)4.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. James A. Helliwell FRCPC (Age 49)M.D., CEO & Director Comp: $457.19kMr. Bruce G. Cousins C.A. (Age 62)CPA, President & CFO Comp: $307.23kDr. Amanda Malone Ph.D. (Age 42)Chief Scientific Officer Comp: $338.8kMr. Paul Anthony Brennan B.Sc.M.Sc., Chief Business OfficerDr. Mark M. Kowalski M.D. (Age 68)Ph.D., Chief Medical Officer Key Competitors3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXView All Competitors EPRXF Stock Analysis - Frequently Asked Questions Should I buy or sell Eupraxia Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eupraxia Pharmaceuticals in the last year. There are currently 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" EPRXF shares. View EPRXF analyst ratings or view top-rated stocks. What is Eupraxia Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Eupraxia Pharmaceuticals' shares. Their EPRXF share price targets range from C$18.00 to C$18.00. On average, they expect the company's share price to reach C$18.00 in the next year. This suggests a possible upside of 326.0% from the stock's current price. View analysts price targets for EPRXF or view top-rated stocks among Wall Street analysts. How have EPRXF shares performed in 2023? Eupraxia Pharmaceuticals' stock was trading at C$2.69 at the beginning of 2023. Since then, EPRXF shares have increased by 57.1% and is now trading at C$4.23. View the best growth stocks for 2023 here. Are investors shorting Eupraxia Pharmaceuticals? Eupraxia Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 5,800 shares, an increase of 13.7% from the October 15th total of 5,100 shares. Based on an average daily volume of 1,400 shares, the short-interest ratio is presently 4.1 days. View Eupraxia Pharmaceuticals' Short Interest. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:EPRXF) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.